Ask AI
ProCE Banner Activity

Phase III MATTERHORN: Final OS and EFS by Pathologic Outcomes With Durvalumab + FLOT vs Placebo + FLOT in Resectable Gastric/GEJ Cancer

Conference Coverage
Slideset

In the final overall survival (OS) analysis of the phase III MATTERHORN trial, combining perioperative durvalumab plus FLOT vs placebo plus FLOT significantly extended OS in patients with resectable gastric or gastroesophageal junction adenocarcinoma.

Released: October 21, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Incyte, and Lilly.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Incyte

Lilly